Plain-English translation of NCT07666347 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing two different injectable treatments for knee osteoarthritis, a common condition where the cartilage in your knee gradually wears down, causing pain and stiffness. Researchers want to compare —a gel-like substance that acts as a cushion in joints—with , which blocks pain signals and muscle tension. Both medications would be injected directly into your knee joint to see which one (if either) works better at reducing your pain and improving how well your knee functions.
Knee arthritis affects millions of people worldwide and causes chronic pain and disability, yet current treatments don't work well for everyone. Injecting medication directly into the joint may be a safer, more effective option than oral medications or surgery, but doctors need to know which injectable treatment works best.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive injections directly into your knee joint three times per week. You'll be assigned to receive either or botulinum toxin injections (the study will determine which group you join). The researchers will monitor your pain levels, knee function, and any side effects throughout the trial to see which treatment works best for reducing your arthritis symptoms.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
Egypt
Sponsor
Tanta University
Enrollment target
~50 participants
Started
June 2026
Primary completion
December 2026
Age range
50 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mohammed S ElSharkawy, MD
Tanta University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.